FDA pharmacologic class
Phosphodiesterase 4 Inhibitor
5 medicines are in FDA's class of phosphodiesterase 4 inhibitors: roflumilast (Zoryve), apremilast (Otezla), crisaborole (Eucrisa), difamilast (Adquey) and ensifentrine (Ohtuvayre). 1 of the 5 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is roflumilast 500 mcg tablet at $0.311 per tablet (NADAC).
Which medicines are phosphodiesterase 4 inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Roflumilast | Zoryve, Daliresp | 15 labelers | $0.311 per tablet 500 mcg tablet | No | No current entry | 0 |
| Apremilast | Otezla | none listed | $90.57 per tablet 30 mg tablet | No | No current entry | 0 |
| Crisaborole | Eucrisa | none listed | $11.68 per gram 2% ointment | No | No current entry | 0 |
| Difamilast | Adquey | none listed | n/a | No | No current entry | 0 |
| Ensifentrine | Ohtuvayre | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price